3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Sarcoma
1
Head & Neck
1
Conditions
Pain, Intractable
1
Neoplasms
1
Bone Neoplasms
1
Interventions
Imatinib Mesylate
3
nilotinib
2
Sunitinib
2
Ibandronic Acid
2
Doxorubicin
2
Cyclophosphamide
2
regorafenib
1
pegylated granulocyte colony-stimulating factor
1
nirogacestat
1
avapritinib
1
anlotinib
1
Zoledronic Acid
1
Tranexamic Acid
1
Thiotepa
1
Ritonavir
1
Radiotherapy
1
Pregabalin
1
Oxaliplatin
1
Nevirapine
1
Midazolam
1
Lopinavir
1
Lithium Carbonate
1
Lead
1
Kyphoplasty
1
Indocyanine Green
1
Ifosfamide
1
Hyperbaric Oxygenation
1
Filgrastim
1
Esomeprazole
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Pregabalin
×
Sarcoma
×
Clear all
NCT00381095
2021-01-20
COPE
Pfizer
Phase 4
Terminated
152 enrolled
14 charts